Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says

Jan 06 2017

• By Sue Sutter

Related Content

Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia

Jan 06 2017

Neurocrine Gets First Drug For Tardive Dyskinesia To FDA

Aug 30 2016

US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?

Jan 03 2017

Repros Therapeutics Needs New Pivotal Trial For Low T Drug Enclomiphene

Dec 01 2015

CNS Therapies Contribute Rising Share Of Breakthrough Designations

Feb 29 2016

Teva Remains Focused On Tardive Dyskinesia After Huntington’s Stumble

May 31 2016

Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says

Sep 06 2016

Purdue's Pain And No Gain: More Analysis Of OxyContin Postmarket Studies Needed

Jun 30 2015

Repros At A Loss After FDA Abruptly Cancels Enclomiphene Panel Review

Oct 30 2015

US FDA Review Management Challenged After Spate Of Complete Response Letters

Nov 21 2016

Related Companies

Neurocrine Biosciences, Inc.

Teva Pharmaceutical Industries Ltd.

Dynavax Technologies Corporation

Repros Therapeutics, Inc.

Purdue Pharma L.P.

Additional Topics

United States Regulation Advisory Committees Drug Review BioPharmaceutical Neurology

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window